您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: CSO & 总经理
所属公司: 圣诺医药
个人简介:
杨博士从事核酸创新药物研发工作30多年。在加入圣诺前,他参与并创建两家开发核酸药品的美国生物科技公司。他曾经担任过多家国际科技公司的顾问,是美国国立卫生研究院三个项目组的评审专家,八家国际期刊的审稿人, 2008-2018年被美国和国内双一流大学聘为兼职教授。杨博士作为新药项目研发总负责人(PI),在过去作为PI承担着多项美国国家核酸药研发项目。杨博士在核酸药物开发领域的创新研究成果得到了同行的一致认同。杨博士于2003年获得美国德克萨斯大学医学院James W. McLaughlin 奖,以表彰他发现抗西尼罗病毒核酸药;杨博士于2005 和2006 连续两年获得纽约科学院奖学金;2012年获得国际核酸药物学会设立的首届青年科学家奖;2017被选为北京大学医学部优秀校友。2022年被选为苏州工业园区创新领军人才。在过去15年间,杨博士100多次应邀出席各种大学、研究所、医药公司和国际生物医药举办的各类会议,并做报告。杨博士先后在国际生物科技领域权威期刊发表了70多篇学术论文和100多篇学术会议论文摘要。杨博士已获得三项美国专利和一项澳大利亚专利,还有多项专利正在审批中。杨博士早年获得北京医科大学学士和医学硕士、欧洲博士、 美国工商管理硕士学位。 Dr. Yang has been engaged in the research and development of innovative nucleic acid drugs for more than 30 years. Prior to joining Sirnaomics, he co-founded two U.S. biotechnology companies that developed nucleic acid based therapeutics. He has served as a consultant for several international companies, a reviewer for three sections of the National Institutes of Health, a reviewer for eight international journals, and was employed as an adjunct professor at university in the United States and China from 2008 to 2018. Dr. Yang has been responsible for a number of national nucleic acid drug R&D projects in the United States as a PI in the past. Dr. Yang's achievements in the field of nucleic acid drug development have been unanimously recognized by his peers. Dr. Yang received the James W. McLaughlin Award from the University of Texas Medical Brance in 2003 for his discovery of anti-West Nile virus nucleic acid therapeuticss; Dr. Yang was awarded a fellowship to the New York Academy of Sciences for two consecutive years in 2005 and 2006; In 2012, he won the first Young Investigator Award established by the Oligonucleotide Therapeutic Society; In 2017, he was selected as an excelent alumnus of Peking University Health Science Center. In 2022, he was selected as the innovation leader of Suzhou Industrial Park. In the past 15 years, Dr. Yang has been invited to attend and give more than 100 conferences held by universities, research institutes, pharmaceutical companies and international biomedicine. Dr. Yang has published more than 70 academic papers and more than 100 abstracts of academic conference papers in authoritative international biotechnology journals. Dr. Yang has been granted three U.S. patents and one Australian patent, with several patents pending. Dr. Yang received his bachelor's and master's degrees in medicine from Beijing Medical University, his Ph.D. in Europe, and his MBA.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 首席医学官
所属公司: 劲方医药科技有限公司
个人简介:
汪裕博士1995年毕业于同济医科大学(武汉)临床医学系。1995-2000年,在上海医科大学(现复旦大学医学院)研究生院外科学系攻读博士学位 (附属中山医院普外科胆道外科)。 2000年7月毕业后在华东医院外科短暂工作。2001年至2004年间,在美国密歇根州Wayne State University医学院Barbara 肿瘤研究所进行肿瘤治疗领域的博士后研究,在相关学术杂志发表多篇文章。2004年回国后,先后在三维生物,礼来制药,葛兰素和赛诺菲亚太研发中心担任肿瘤领域医学负责人从事肿瘤药物的临床开发。2013-2016年,在诺华生物医学研究院临床肿瘤转化医学部门作为全球早期临床项目和试验的负责人,进行肿瘤产品临床早期研究,领导了数个first-in-class肿瘤靶向产品在全球的临床研究。汪裕博士于2016年11月-2017年12月作为首席科学官就职于博纳西亚医药科技有限公司。2018年1月创立详妍咨询,曾兼任国内多个上市医药公司、生物技术公司及学术研究机构高级医学顾问、外聘专家,和誉生物首席医学官。2020年至今任劲方医药首席医学官。
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 董事长/CEO
所属公司: 海创药业股份有限公司
个人简介:
海创药业股份有限公司创始人、董事长兼总经理(总裁),四川大学特聘教授、博士生导师、瑞士洛桑大学化学博士,美国斯克利普斯研究所博士后研究员、国家级人才专家、四川省杰出人才、成都天府海智计划专家、成都高新区金熊猫成就奖获得者、成都蓉漂计划引进人才,四川省第九批学术与技术带头人。世界500强艾伯维(Abbvie)制药、拜耳制药(Bayer)美国研究院等近20年药物研发经验。曾任白鹭医药技术(上海)有限公司首席科技官,成都睿智化学研究有限公司总经理,推动10个新药项目分别进入IND申报、I-III期临床研究阶段。共发表专利60余篇,论文70余篇。Founder and Chief Executive Officer of Hinova Pharmaceuticals Inc. ⚫Past General Manager, Chengdu ChemPartner Co.Ltd., China⚫Past Vice President of Medicinal Chemistry, Shanghai ChemPartner Co.Ltd., China-Past Chief ScientificOfficer, Egret Pharma (Shanghai)Ltd, Shanghai, China⚫Past Senior Scientistll and project leader, Bayer Healthcare, Pharmaceutical product Division, USA.PastSenior Research Scientist,AbbVie, Abbott Park, Pharmaceutical Product Division, USA⚫Inventor and co-inventor of more than 20 compounds that are in Phase l,ll and ll clinical trials(influenzaneuraminidase inhibitor, VEGFR inhibitor, SGLT2 inhibitor,AR inhibitor).
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 首席科学官
所属公司: 艾美斐生物医药有限公司
个人简介:
王建飞  博士 南京艾美斐生物医药科技有限公司 首席科学官 比较医学高级医师,国际AAALAC认可委员会常务理事,中科院上海生命科学研究院教授(兼),上海科学院特聘教授。加拿大卡尔加里大学分子细胞学博士学位,在美国哈佛大学医学院从事博士后研究。 曾任美国宾夕法尼亚大学比较医学住院医师4年,并获执医资质,任加拿大艾尔伯塔大学医学院外科系教授。 曾担任GSK中国研发中心整合生物技术科研部负责人,建立了完整的临床前研发平台,为公司的数十个项目提供靶点验证、先导化合物优化、药效学和药代动力学研究提供科学及技术支持,获得GSK中国研发中心包括金奖在内的多次表彰,GSK全球整合生物平台科研部领导之一, 并成功地推动多个新药研发项目完成临床申报,进入临床试验,被评为高级GSK研究员(Senior GSK Fellow,公司科研最高级别学者)。在转化医学研究方面拥有超过28年的经验,在世界著名的国际期刊上发表了70多篇论文,10多篇书刊章节,获多项专利。Dr. Jianfei WangChief Scientific Officer (CSO), Member of the BoardSenior Physician in Comparative Medicine Professor of CAS Shanghai Institute of Biological Sciences (adjunct)Honorary Head and Professor, Institute of Translational Medicine, Shanghai Academy of SciencesDistinguished professor of Yunnan Agricultural UniversityDr. Wang received a Ph.D. in Molecular Cell Biology from the University of Calgary, Canada and completed his residency in Comparative Medicine at the University of Pennsylvania, USA. He then pursued his postdoctoral research at Harvard Medical School. He was later appointed as a faculty member in the Department of Surgery at the Faculty of Medicine at the University of Alberta, Canada, before returning to China.Dr. Wang is a seasoned executive with solid knowledge of both small and large molecule drugs and extensive experience in program insight for shaping R&D strategy. He has over 28 years of translational medicine research and team management experience in multinational pharmaceutical companies. At GSK R&D China, Dr. Wang established an integrated preclinical platform that provided support for target identification, validation, lead compound optimization, DMPK studies, discovery histopathology, safety assessment, and blood-brain barrier penetration for many projects that proceeded to candidate selections and clinical trials. Due to his distinguished contributions, Dr. Wang received many awards from GSK R&D China. He also served as a core member of the GSK global translational medicine leadership team and was elected as a Senior GSK Fellow, the highest level of scientific research scholar.Dr. Wang’s contributions to translational medicine & drug discovery are recognized by being granted numerous distinguished awards, including an outstanding scientist by numerous national and international organizations. He has published more than 70 papers in prestigious international journals and owns multiple patents.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务